Sickle cell anemia is an inherited blood disorder where red blood cells mutate from their normal disc shape into rigid, crescent-shaped cells that stick together, block blood vessels, and die prematurely. The result is a disease that touches nearly every organ system — causing severe pain crises, chronic anemia, organ damage, and a life expectancy that’s still roughly 20 years shorter than the general population, even with modern treatment.
About 100,000 people in the United States live with sickle cell disease, and it occurs in approximately 1 in 365 African-American births. But sickle cell anemia isn’t limited to one ethnicity — it’s also prevalent in people of Mediterranean, Middle Eastern, Indian, and Central/South American descent. If you’re reading this because you or someone you love has been diagnosed, here’s what actually matters clinically.
What Causes Sickle Cell Anemia?
Sickle cell anemia is caused by a point mutation in the HBB gene on chromosome 11. This single amino acid substitution (valine replacing glutamic acid at position 6) produces an abnormal form of hemoglobin called hemoglobin S (HbS). When HbS loses oxygen, it polymerizes — the hemoglobin molecules stack together like rods inside the red blood cell, forcing it into that characteristic sickle shape.
You need two copies of the sickle gene (one from each parent) to have sickle cell anemia (genotype HbSS). If you inherit only one copy, you have sickle cell trait (HbAS), which generally doesn’t cause symptoms but means you’re a carrier. Two carriers have a 25% chance of having a child with sickle cell anemia with each pregnancy.
Symptoms of Sickle Cell Anemia
Symptoms typically appear around 5-6 months of age, when fetal hemoglobin (HbF) levels naturally decline and HbS takes over. The hallmark symptoms include:
- Chronic anemia — hemoglobin often runs 6-8 g/dL (normal is 12-16 g/dL). Patients feel fatigued, weak, and short of breath because sickle cells only live 10-20 days vs. the normal 120 days.
- Vaso-occlusive pain crises — the most common reason for ER visits. Sickled cells clog small blood vessels, cutting off blood supply. Pain is often excruciating and can hit the chest, abdomen, bones, and joints.
- Frequent infections — the spleen, which filters bacteria, is damaged early (functional asplenia often by age 5). Patients are especially vulnerable to encapsulated organisms like Streptococcus pneumoniae.
- Dactylitis (hand-foot syndrome) — swollen, painful hands and feet, often the very first sign in infants.
- Delayed growth and puberty in children and adolescents.
- Vision problems from sickle cell retinopathy.
- Jaundice from chronic hemolysis (breakdown of red blood cells).
Serious Complications
Sickle cell anemia isn’t just about pain. Over time, repeated vaso-occlusion and hemolysis cause cumulative organ damage:
| Complication | What Happens | Frequency |
|---|---|---|
| Acute chest syndrome | Pulmonary vaso-occlusion + infection; leading cause of death in adults with SCD | ~50% of patients experience at least one episode |
| Stroke | Cerebral vessel occlusion; can occur in children as young as 2 | 11% of patients by age 20 without screening |
| Splenic sequestration | Blood pools in spleen, causing rapid drop in hemoglobin — a medical emergency | Most common in children under 5 |
| Avascular necrosis | Bone tissue death, especially femoral head | Up to 50% by age 35 |
| Chronic kidney disease | Sickle nephropathy from repeated medullary ischemia | Proteinuria in 20-40% of adults |
| Pulmonary hypertension | Elevated pulmonary artery pressure from chronic hemolysis | 6-11% of adults |
How Sickle Cell Anemia Is Diagnosed
In the U.S., all 50 states include sickle cell screening in their newborn screening panel. A heel-prick blood sample is tested using hemoglobin electrophoresis or high-performance liquid chromatography (HPLC). A result showing predominantly HbS with absent or minimal HbA confirms sickle cell anemia (HbSS).
For older patients or those born outside the U.S., diagnosis involves a complete blood count (CBC) — which typically shows hemoglobin of 6-8 g/dL, elevated reticulocyte count, and elevated bilirubin — along with a hemoglobin electrophoresis to identify the specific hemoglobin type. A peripheral blood smear will often show sickle-shaped cells, target cells, and Howell-Jolly bodies (indicating splenic dysfunction).
Treatment Options for Sickle Cell Anemia
Disease-Modifying Medications
Hydroxyurea remains the backbone of sickle cell treatment. It works by boosting fetal hemoglobin (HbF) production, which inhibits HbS polymerization. Clinical trials show hydroxyurea reduces pain crises by 44%, cuts hospitalizations roughly in half, and reduces mortality. The FDA approved it for adults in 1998 and children ages 2+ in 2017. Despite this, it remains underutilized — only about 25% of eligible patients are on it.
Three newer medications are now FDA-approved:
- Voxelotor (Oxbryta) — binds to HbS and prevents polymerization; improves hemoglobin levels by ~1 g/dL.
- Crizanlizumab (Adakveo) — a monoclonal antibody that blocks P-selectin, reducing cell adhesion and vaso-occlusion. Reduced annual crises by 45% in the SUSTAIN trial.
- L-glutamine (Endari) — an amino acid supplement that reduces oxidative stress in sickle cells.
Curative Therapies
Bone marrow (stem cell) transplant is the only established cure. With a matched sibling donor, cure rates exceed 90%, but only about 18% of patients have a suitable donor, and the procedure carries significant risks including graft-versus-host disease.
Gene therapy is the newest frontier. In December 2023, the FDA approved two gene therapies for sickle cell anemia: Casgevy (the first CRISPR-based gene therapy ever approved) and Lixgenia. Both require myeloablative conditioning and are extraordinarily expensive ($2-3 million), but they represent a potential cure without needing a donor.
Supportive Care and Lifestyle
- Hydration — dehydration concentrates HbS and promotes sickling. Aim for 8-10 glasses of water daily.
- Penicillin prophylaxis — recommended from age 2 months to at least age 5 to prevent pneumococcal sepsis.
- Vaccinations — pneumococcal, meningococcal, and annual flu vaccines are essential given functional asplenia.
- Folic acid supplementation — 1 mg daily to support the increased red blood cell production.
- Transcranial Doppler (TCD) screening — annual screening for children ages 2-16 to identify stroke risk. Chronic transfusion programs can reduce stroke risk by 92%.
- Avoid triggers — extreme cold, high altitude, overexertion, and dehydration can all precipitate a crisis.
When to Go to the Emergency Room
Not every pain episode requires an ER visit, but certain situations are medical emergencies:
- Fever above 101.3°F (38.5°C) — in a functionally asplenic patient, this could signal overwhelming sepsis
- Chest pain, cough, or difficulty breathing (possible acute chest syndrome)
- Sudden severe headache, weakness, or speech changes (possible stroke)
- Sudden enlargement of the spleen with worsening pallor in a child (splenic sequestration)
- Priapism lasting longer than 4 hours
- Pain that doesn’t respond to home pain management within 1-2 hours
Frequently Asked Questions
What’s the life expectancy for someone with sickle cell anemia?
With modern treatment, median life expectancy is approximately 45-55 years in the U.S. — a dramatic improvement from the 1970s when most patients didn’t survive childhood. Hydroxyurea, newborn screening, penicillin prophylaxis, and stroke prevention programs deserve most of the credit. Gene therapy may push these numbers further in the coming decades.
Can you have sickle cell trait and never know it?
Absolutely. Most people with sickle cell trait (HbAS) are completely asymptomatic and live normal lives. However, trait carriers can experience complications under extreme conditions — intense exercise at high altitude, severe dehydration, or during anesthesia. The NCAA now requires sickle cell trait testing for all Division I athletes.
Is sickle cell anemia the same as sickle cell disease?
Not exactly. Sickle cell disease (SCD) is the umbrella term covering all genotypes that cause sickling — including HbSS (sickle cell anemia), HbSC disease, and HbS-beta thalassemia. Sickle cell anemia (HbSS) is typically the most severe form.
Why does hydroxyurea work if it’s a chemotherapy drug?
At the low doses used for sickle cell disease, hydroxyurea primarily works by reactivating fetal hemoglobin (HbF) production. HbF “dilutes” the HbS inside each red blood cell, making polymerization and sickling much less likely. The side effects at these doses are mild compared to chemotherapy-level dosing — most patients tolerate it well with regular blood count monitoring.
Can sickle cell anemia be cured?
Yes — bone marrow transplant from a matched sibling donor cures over 90% of patients, and the newly approved gene therapies (Casgevy and Lixgenia) offer a cure without needing a donor. The catch: transplant requires a matching donor most patients don’t have, and gene therapies cost $2-3 million with limited availability. For most patients today, disease management with hydroxyurea and supportive care remains the standard approach.
